Karyopharm Therapeutics Inc

This phase 2 study tests the drug selinexor against standard treatments in 112 people with myelofibrosis who have already tried JAK inhibitors. The main goal is to see if selinexor can shrink the spleen and improve symptoms. Participants are randomly assigned to receive either se…

This study tests an experimental drug called selinexor in adults with diffuse large B-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the drug can shrink tumors or control the disease. Participants must have no other proven treatment opt…

This study tests whether adding the oral drug selinexor to standard chemotherapy (R-GDP) can help people with relapsed or refractory diffuse large B-cell lymphoma who cannot receive a stem cell transplant or CAR-T therapy. About 500 participants will receive either selinexor at o…

This study tests whether the drug selinexor can help keep advanced or recurrent endometrial cancer from growing back after initial chemotherapy. About 276 adults whose cancer has a normal p53 gene and who responded to platinum-based chemo will receive either selinexor or a placeb…

This study tests whether adding the drug selinexor to the standard treatment ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a type of bone marrow cancer. About 353 adults who have not yet been treated for their condition will take either the combin…

This study aimed to test the drug selinexor combined with other treatments for people with a type of blood cancer called diffuse large B-cell lymphoma that had come back or stopped responding to therapy. The trial was planned in two phases to first find the safest dose and then c…